Company: INMB
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001213900-25-104141
Chunk: 82

Company: Inmune Bio, Inc.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 2
Chunk 82
---
22.3 million of cash during the nine months ended September 30, 2024, resulting from our loss of $32.9 million, partially
offset by changes in our net operating assets and liabilities of $4.6 million and non-cash stock-based compensation of $5.8 million. The
change in our net operating assets and liabilities was mainly due to an increase in accounts payable and accrued liabilities of $2.7 million,
a decrease in research and development tax receivable of $0.8 million, a decrease in prepaid expenses of $0.6 million and a decrease in
other tax receivable of $0.2 million. 

Investing Activities

During the nine months ended
September 30, 2025, the Company acquired $0.9 million of equipment to be used in its CORDStrom clinical program.

Financing Activities

During the nine months ended
September 30, 2025, the Company sold 1,304,707 shares of common stock under its ATM program for net proceeds of $10.1 million.

During June 2025, the Company
sold 3,000,000 shares of its common stock in a registered direct offering in exchange for gross proceeds of $18.9 million (net proceeds
of $17.4 million).

During the nine months ended
September 30, 2024, the Company sold 247,126 shares of its common stock under its ATM programs for net proceeds of approximately $2.4
million.

During the nine months ended
September 30, 2024, the Company sold 3,898,852 shares of its common stock and 3,898,852 warrants to purchase its common stock in registered
direct offerings for net proceeds of approximately $25.4 million.

During the nine months ended
September 30, 2024, the Company repaid $7.5 million of its debt.

Critical Accounting Estimates

Our discussion and analysis
of our financial condition and results of operations is based upon our unaudited condensed consolidated financial statements, which have
been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of these financial
statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses. Actual results
may differ from these estimates. Our critical accounting estimates are discussed in our Annual Report on Form 10-K for the fiscal year
ended December 31, 2024, and there have